Study of finasteride application during the off-cycle in patients with advanced prostate cancer treated with intermittent androgen blockade.
- VernacularTitle:非那雄胺在晚期前列腺癌间歇性雄激素阻断治疗间隙期的应用
- Author:
Wei CHEN
;
Zhiliang WENG
;
Yeping LI
;
Zhexian DENG
;
Haihan WU
;
Chengdi LI
;
Xiuling WU
;
Kaiyuan YU
- Publication Type:Journal Article
- Keywords:
Prostatic neoplasms;
Finasteride;
Disease progression;
Antineoplasticprotocols
- From:
Chinese Journal of Geriatrics
2008;27(11):815-817
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the finasteride application during the off-cycle of intermittent androgen blockade (IAB) in patients with advanced prostate cancer treated with IAB.MethodsEighty-seven patients with advanced prostate cancer were divided into two groups: forty-nine patients received IAB (group A), and thirty-eight patients underwent IAB and finasteride during the off-cycle of IAB (group B). The time of treatment cycle and the time to disease progression were compared between the two groups. ResultsThe patients in group A completed 89 treatment cycles and the mean cycle length was (12.8±5.4) months [treatment time and non-treatment time were (6.6±3.5) months and (7.1±4.8) months, respectively]. The patients in group B completed 85 cycles and the mean cycle length was (15.3±5.9) months [treatment time and non-treatment time were (6.9±3.2) months and (9.2v±3.9) months, respectively]. There was a significant difference between group A and B in the mean cycle length and the non-treatment time (P=0.0428,P=0.03).The 3-year progression rate was ( 34.8±3.5 )% in group A and ( 28.4±2.7)% in groups B ( P=0.035). ConclusionsThe application of finasteride during the off-cycle of IAB in patients with advanced prostate cancer treated with intermittent androgen blockade (IAB) can delay progression of advanced prostate cancer.
